Skip to main content

Table 6 Results of this analysis

From: Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials

Outcomes reported No of studies involved (n) OR with 95% CI P values I2 (%)
Drug discontinuation 9 1.35 [1.06–1.72] 0.01 31
Serious AEs 7 1.01 [0.79–1.29] 0.93 0
Deaths 5 1.13 [0.43–2.94] 0.80 0
UTIs 7 0.93 [0.70–1.23] 0.61 0
P. dizziness 3 1.51 [0.42–5.37] 0.53 0
Hypoglycemia 5 0.96 [0.81–1.13] 0.60 0
Any AEs 8 1.04 [0.85–1.28] 0.72 52
  1. Abbreviations: AEs adverse events, UTIs urinary tract infections, P. dizziness postural dizziness, OR odds ratios, CI confidence intervals